BidaskClub downgraded shares of Axovant Sciences (NASDAQ:AXON) from a sell rating to a strong sell rating in a research note published on Wednesday, September 12th.
A number of other equities analysts have also commented on AXON. ValuEngine lowered Axovant Sciences from a hold rating to a sell rating in a research note on Monday, June 11th. Zacks Investment Research lowered Axovant Sciences from a strong-buy rating to a hold rating in a research note on Friday, June 15th. Oppenheimer restated a hold rating on shares of Axovant Sciences in a research report on Monday, July 9th. HC Wainwright restated a buy rating on shares of Axovant Sciences in a research report on Thursday, June 7th. Finally, Chardan Capital restated a hold rating and set a $4.00 target price on shares of Axovant Sciences in a research report on Wednesday, June 6th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $5.00.
Axovant Sciences stock traded down $0.02 on Wednesday, reaching $2.08. The company’s stock had a trading volume of 449,161 shares, compared to its average volume of 2,790,191. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.34 and a current ratio of 2.34. The firm has a market cap of $295.44 million, a P/E ratio of -1.01 and a beta of -0.01. Axovant Sciences has a twelve month low of $1.02 and a twelve month high of $7.92.
Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.33). On average, equities research analysts predict that Axovant Sciences will post -1.67 earnings per share for the current year.
In other news, Director George Bickerstaff bought 25,000 shares of the company’s stock in a transaction dated Thursday, August 9th. The stock was bought at an average price of $2.07 per share, for a total transaction of $51,750.00. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $103,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.00% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its holdings in Axovant Sciences by 1,627.0% in the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 58,541 shares during the last quarter. BlackRock Inc. increased its holdings in Axovant Sciences by 3.4% in the first quarter. BlackRock Inc. now owns 3,012,515 shares of the biotechnology company’s stock valued at $4,006,000 after purchasing an additional 100,296 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Axovant Sciences in the second quarter valued at about $338,000. Paloma Partners Management Co bought a new stake in Axovant Sciences in the second quarter valued at about $356,000. Finally, JPMorgan Chase & Co. increased its holdings in Axovant Sciences by 2,519.0% in the first quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 176,227 shares during the last quarter. Institutional investors own 9.38% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
See Also: What is the NASDAQ?
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.